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1. INTRODUCTION {#clc23282-sec-0006}
===============

Venous thromboembolism (VTE) is a common and severe thrombotic disorder. Its age‐ and sex‐adjusted incidence rate is estimated to be around 1.2‐1.4 per 1000 person‐years, and its 30‐day mortality rate could reach up to 10%.[2](#clc23282-bib-0002){ref-type="ref"}, [3](#clc23282-bib-0003){ref-type="ref"} Previous studies demonstrated that agedness, major surgical operations, cancer, gestation, and sequential oral contraceptives could increase susceptibility to VTE.[4](#clc23282-bib-0004){ref-type="ref"}, [5](#clc23282-bib-0005){ref-type="ref"} Nevertheless, many people who were exposed to these risk factors did not ultimately develop VTE, which suggested that genetic factors were also involved in its development.

Plasminogen activator inhibitor‐1 (PAI‐1) is a serine protease inhibitor, and it is involved in the regulation of fibrinolysis and thrombosis via inhibiting biological activities of tissue plasminogen activator (t‐PA) and urokinase plasminogen activator (u‐PA).[6](#clc23282-bib-0006){ref-type="ref"} Previous basic researches showed that blockage of PAI‐1 could lead to thrombus degradation, whereas activation of PAI‐1 could accelerate thrombus formation.[7](#clc23282-bib-0007){ref-type="ref"}, [8](#clc23282-bib-0008){ref-type="ref"} So if a gene polymorphism could alter the expression level or protein structure of PAI‐1, it is possible that this polymorphism may also affect individual susceptibility to thrombotic disorders like VTE.

In recent years, many investigations reported findings regarding potential associations between *PAI‐1* rs1799889 A/G polymorphism and VTE.[9](#clc23282-bib-0009){ref-type="ref"}, [10](#clc23282-bib-0010){ref-type="ref"}, [11](#clc23282-bib-0011){ref-type="ref"}, [12](#clc23282-bib-0012){ref-type="ref"} Nevertheless, these findings were somehow inconsistent. In this meta‐analysis, we aimed to better clarify the relationship between *PAI‐1* rs1799889 A/G polymorphism and VTE. We will also perform comprehensive analyses to investigate the effects of ethnic background, type of disease, and established risk factors of VTE (Factor V Leiden mutation, cancer status, and recent major surgery) on genetic association between *PAI‐1* rs1799889 A/G polymorphism and VTE.

2. MATERIALS AND METHODS {#clc23282-sec-0007}
========================

This meta‐analysis was written in accordance with PRISMA guideline.[13](#clc23282-bib-0013){ref-type="ref"} We also created an Open Science Framework (osf.io) account to make this meta‐analysis more publicly available.

2.1. Literature search and inclusion criteria {#clc23282-sec-0008}
---------------------------------------------

We searched PubMed, Web of Science, Embase, and CNKI using the following key words: "plasminogen activator inhibitor‐1," "PAI‐1," "plasminogen activator inhibitor 1," "PAI1," "serpin family E member 1," "SERPINE1," "polymorphism," "variant," "variation," "mutation," "SNP," "venous thromboembolism," "VTE," "deep vein thrombosis," "DVT," "pulmonary embolism," and "PE." The latest literature searching update was conducted in June 2019.

To be included in this meta‐analysis, some criteria must be met: (a) About *PAI‐1* rs1799889 A/G polymorphism and VTE in human beings; (b) providing distributions of genotypes or alleles in cases and controls; (c) Full text in English or native language of the authors (Chinese) is retrievable. Studies were deemed to be ineligible for inclusion if: (a) Not about *PAI‐1* rs1799889 A/G polymorphism and VTE; (b) studies that were not carried out in humans; (c) case reports or case series; (d) reviews and comments. If we found repeated publications during literature searching, only the most comprehensive study was included for analyses.

2.2. Data extraction and quality assessment {#clc23282-sec-0009}
-------------------------------------------

Following information was extracted by two authors: the last name of the first author and publication year, country of the principal investigator and ethnicity of study participants, type of disease, total sample size of each study, and the distribution of *PAI‐1* rs1799889 A/G polymorphism in cases and controls. We also calculated the probability value (*P* value) of Hardy‐Weinberg equilibrium.

The authors used Newcastle‐Ottawa scale (NOS) to assess the quality of eligible studies.[14](#clc23282-bib-0014){ref-type="ref"} The score range of NOS is between zero and nine, when a study got a score of seven or more, we considered that the methodology of this study is good.

Two authors extracted data and assessed quality of eligible publications. The authors wrote to the leadings authors for additional information if essential information was found to be incomplete.

2.3. Statistical analyses {#clc23282-sec-0010}
-------------------------

Review Manager was used to combine the results of eligible studies. *Z* test was employed to assess whether *PAI‐1* rs1799889 A/G polymorphism was significantly associated with VTE, with the statistical significance *P* level set at .05. We used *I* ^2^ statistics to assess between‐study heterogeneities. We used Random‐effect models (DerSimonian‐Laird method) to combine the results if *I* ^2^ is larger than 50%. Otherwise, fixed‐effect models (Mantel‐Haenszel method) were used to combine the results. We also conducted subgroup analyses by ethnicity of participants, type of disease and whether the study subjects had established risks of VTE. We examined the stability of combined results by deleting one study each time and combining the results of the remaining studies. We used funnel plots to estimate whether our combined results may be influenced by publication biases.

This article does not contain any studies with human participants or animals performed by any of the authors, thus ethical approval is not required.

3. RESULTS {#clc23282-sec-0011}
==========

3.1. Characteristics of included studies {#clc23282-sec-0012}
----------------------------------------

One thousand eight hundred and twenty‐nine studies were identified by our comprehensive literature searching. One hundred and thirty‐three studies were retrieved for eligibility assessment after exclusion of irrelevant and duplicate articles. Another eighty‐five articles were further excluded by us because these articles did not meet the inclusion criteria that were set forth for this meta‐analysis. Totally forth‐eight studies containing 5731 cases and 9075 controls were ultimately included in this meta‐analysis (see Figure [1](#clc23282-fig-0001){ref-type="fig"}). Table [1](#clc23282-tbl-0001){ref-type="table"} presented essential data extracted from included studies.

![Flowchart of study selection for the present study](CLC-42-1232-g001){#clc23282-fig-0001}

###### 

The characteristics of included studies for *PAI‐1* rs1799889 A/G polymorphism and VTE

                                                                   Genotype distribution (AA/AG/GG)                           
  ----------------------- ---------- ------------ ----- ---------- ---------------------------------- ------------- --------- ---
  Akar 2000               Turkey     Caucasian    DVT   136/113    38/77/21                           28/57/28      0.925     7
  Akhter 2010             India      West Asian   DVT   110/110    48/54/8                            29/56/25      0.838     8
  Alfirevic 2010          Croatia    Caucasian    VTE   100/105    31/52/17                           33/55/17      0.457     7
  Arslan 2011             Turkey     Caucasian    DVT   33/33      14/19/0                            12/18/3       0.305     7
  Barcellona 2013         Italy      Caucasian    VTE   402/466    72/265/65                          61/305/100    \<0.001   7
  Bedencic 2008           Slovenia   Caucasian    VTE   295/223    93/157/45                          63/115/45     0.569     7
  Bezgin 2018             Turkey     Caucasian    VTE   310/287    74/160/76                          81/137/69     0.460     7
  Bezgin 2018             Turkey     Caucasian    DVT   247/287    59/130/58                          81/137/69     0.460     7
  Bezgin 2018             Turkey     Caucasian    PE    20/287     5/11/4                             81/137/69     0.460     7
  Chen 2005               China      East Asian   DVT   120/120    46/55/19                           42/51/27      0.135     8
  Cushman 2004            USA        Caucasian    VTE   138/469    37/68/33                           119/248/102   0.202     9
  D\'Amico 2015           Italy      Caucasian    VTE   243/622    NA                                 NA            NA        7
  Eroglu 2006             Turkey     Caucasian    DVT   45/80      10/30/5                            33/41/6       0.161     7
  Espinosa 2002           Spain      Caucasian    VTE   38/100     8/19/11                            21/52/27      0.662     7
  Farajzadeh 2014         Iran       West Asian   VTE   193/500    50/83/60                           353/91/56     \<0.001   8
  Ferrara 2013            Italy      Caucasian    DVT   168/70     139/27/2                           62/7/1        0.158     7
  Folsom 2003             USA        Mixed        VTE   308/640    77/160/68                          173/326/141   0.590     8
  Giannaki 2013           Greece     Caucasian    VTE   102/102    NA                                 NA            NA        7
  Grubic 1996             Slovenia   Caucasian    DVT   83/50      25/50/8                            15/29/6       0.160     8
  Gu 2014                 China      East Asian   VTE   198/212    146/35/17                          123/55/34     \<0.001   8
  Hasan 2006              Egypt      Caucasian    DVT   48/40      20/22/6                            8/16/16       0.292     7
  Kaya 2013               Turkey     Caucasian    VTE   80/79      19/43/18                           29/36/14      0.628     7
  Kotwal 2013             USA        Mixed        PE    12/12      NA                                 NA            NA        7
  Kuhli‐Hattenbach 2017   Germany    Caucasian    VTE   25/241     6/16/3                             56/122/63     0.837     7
  Kumari 2014             India      West Asian   VTE   93/102     31/39/23                           27/53/22      0.674     7
  Kupeli 2011             Turkey     Caucasian    VTE   80/103     24/38/18                           28/57/28      0.925     7
  Kupeli 2011             Turkey     Caucasian    PE    51/103     15/27/9                            28/57/28      0.925     7
  Lichy 2007              Germany    Caucasian    VTE   76/195     21/40/15                           61/91/43      0.413     7
  Mansilha 2005           Portugal   Caucasian    DVT   81/88      22/40/19                           21/39/28      0.311     7
  Meglic 2003             Slovenia   Caucasian    VTE   30/53      7/16/7                             14/29/10      0.464     8
  Morange 2000            France     Caucasian    VTE   168/214    50/79/39                           50/105/59     0.804     7
  Oguzulgen 2009          Turkey     Caucasian    PE    143/181    36/63/44                           46/94/41      0.595     7
  Onur 2012               Turkey     Caucasian    VTE   28/50      12/10/6                            17/19/14      0.093     8
  Ozkan 2012              Turkey     Caucasian    VTE   158/134    91/56/11                           66/57/11      0.789     8
  Pop 2014                Romania    Caucasian    DVT   168/162    51/71/46                           38/95/29      0.025     7
  Prabhudesai 2017        India      West Asian   VTE   87/251     23/38/26                           82/132/37     0.170     8
  Ridker 1997             USA        Mixed        VTE   121/495    36/59/26                           133/247/115   0.988     7
  Ringelstein 2012        Germany    Caucasian    VTE   136/1054   44/72/20                           326/521/207   0.964     8
  Ringwald 2009           Germany    Caucasian    DVT   50/85      11/29/10                           21/42/22      0.915     8
  Russo 2015              Italy      Caucasian    VTE   113/101    26/68/19                           31/51/19      0.807     7
  Sartori 1998            Sweden     Caucasian    DVT   70/100     21/42/7                            26/50/24      0.997     7
  Sartori 2003            Italy      Caucasian    DVT   73/76      29/34/10                           23/42/11      0.244     7
  Schenk 2008             Germany    Caucasian    VTE   69/238     23/41/5                            66/122/50     0.645     7
  Seguí 2000              Spain      Caucasian    DVT   190/93     NA                                 NA            NA        7
  Stegnar 1998            Slovenia   Caucasian    VTE   158/145    46/88/24                           38/76/31      0.541     7
  Tàssies 2000            Spain      Caucasian    VTE   59/100     17/29/13                           27/52/21      0.662     7
  Vesa 2016               Romania    Caucasian    DVT   127/114    42/51/34                           26/66/22      0.089     8
  Visanji 2000            UK         Caucasian    VTE   99/99      39/45/15                           26/43/30      0.196     7
  Visanji 2000            UK         Caucasian    PE    28/99      12/13/3                            26/43/30      0.196     7
  Vuckovic 2018           Serbia     Caucasian    VTE   100/100    NA                                 NA            NA        8
  Yioti 2013              Greece     Caucasian    VTE   38/44      NA                                 NA            NA        7
  Zhou 2005               China      East Asian   DVT   29/24      8/17/4                             6/14/4        0.392     7

Abbreviations: DVT, deep vein thrombosis; HWE, Hardy‐Weinberg equilibrium; NA, not available; NOS, Newcastle‐Ottawa scale; *PAI‐1*, plasminogen activator inhibitor‐1; PE, pulmonary embolism; VTE, venous thromboembolism.

3.2. Meta‐analysis results {#clc23282-sec-0013}
--------------------------

*PAI‐1* rs1799889 A/G polymorphism was found to be significantly associated with VTE in Caucasians (dominant comparison: AA vs AG + GG, odds ratio \[OR\] 1.20, 95% confidence interval \[CI\] 1.09‐1.32; recessive comparison: GG vs AA + AG, OR 0.84, 95% CI 0.76‐0.94; allele comparison: A vs G, OR 1.08, 95% CI 1.02‐1.15) and East Asians (dominant comparison: AA vs AG + GG, OR 1.60, 95% CI 1.17‐2.19; allele comparison: A vs G, OR 1.53, 95% CI 1.21‐1.93). Further analyses revealed similar significant associations in the DVT (recessive model: GG vs AA + AG, OR 0.73, 95% CI 0.53‐0.99; allele model: A vs G, OR 1.13, 95% CI 1.02‐1.25) subgroup, yet no any positive results regarding PE were detected in this meta‐analysis (see Table [2](#clc23282-tbl-0002){ref-type="table"}). We also performed stratified analyses to explore the effects of established risk factors of VTE on observed genetic associations between *PAI‐1* rs1799889 A/G polymorphism and VTE, and we found positive results in these with Factor V Leiden mutation, whereas no any significant associations were detected in these with cancer or these who recently had a major surgery operation.

###### 

Results of overall and subgroup analyses for *PAI‐1* rs1799889 A/G polymorphism and VTE

                                Dominant comparison (AA vs AG + GG)   Recessive comparison (GG vs AA + AG)   Over‐dominant comparison (AG vs AA + GG)   Allele comparison (A vs G)                                                                                                      
  ----------------- ----------- ------------------------------------- -------------------------------------- ------------------------------------------ ---------------------------- ----------------------- ----- ------ ------------------ ----- ------------ ----------------------- -----
  Overall           5731/9075   0.30                                  1.10 (0.92‐1.32)                       78%                                        0.11                         0.87 (0.73‐1.03)        65%   0.57   1.04 (0.92‐1.17)   55%   0.21         1.04 (0.98‐1.10)        55%
  Caucasian         4460/6609   **0.0002**                            **1.20 (1.09--1.32)**                  49%                                        **0.003**                    **0.84 (0.76‐0.94)**    35%   0.73   1.02 (0.93‐1.11)   21%   **0.01**     **1.08 (1.02‐1.15)**    31%
  East Asian        347/356     **0.004**                             **1.60 (1.17--2.19)**                  34%                                        0.06                         0.71 (0.50‐1.02)        21%   0.28   0.83 (0.60‐1.16)   38%   **0.0004**   **1.53 (1.21--1.93)**   49%
  West Asian        483/963     0.66                                  0.75 (0.20‐2.80)                       96%                                        0.54                         1.36 (0.51‐3.65)        91%   0.80   1.12 (0.47‐2.66)   92%   0.56         0.75 (0.28‐1.99)        97%
  DVT               1778/1645   0.06                                  1.16 (0.99‐1.36)                       36%                                        **0.05**                     **0.73 (0.53--0.99)**   55%   0.84   1.02 (0.88‐1.17)   46%   **0.02**     **1.13 (1.02--1.25)**   47%
  PE                254/682     0.47                                  1.14 (0.80‐1.61)                       0%                                         0.44                         0.75 (0.36‐1.57)        65%   0.41   0.88 (0.64‐1.20)   0%    0.57         1.11 (0.77‐1.60)        55%
  Factor V Leiden   993/1870    **0.01**                              **1.29 (1.06‐1.57)**                   5%                                         0.06                         0.68 (0.46‐1.02)        65%   0.92   0.99 (0.83‐1.19)   0%    **0.03**     **1.24 (1.02‐1.52)**    60%
  Cancer            264/297     0.91                                  1.03 (0.57‐1.87)                       57%                                        0.46                         0.81 (0.45‐1.43)        0%    0.91   0.98 (0.70‐1.38)   31%   0.46         1.10 (0.85‐1.42)        50%
  Surgery           91/121      0.41                                  1.28 (0.71‐2.32)                       0%                                         0.41                         0.73 (0.35‐1.54)        0%    1.00   1.00 (0.52‐1.91)   0%    0.72         1.08 (0.71‐1.64)        0%

*Note*: The values in bold represent there is statistically significant differences between cases and controls.

Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; NA, not available; OR, odds ratio; *PAI‐1*, plasminogen activator inhibitor‐1; PE, pulmonary embolism; VTE, venous thromboembolism.

3.3. Sensitivity analyses {#clc23282-sec-0014}
-------------------------

We examined the stability of combined results by deleting one study each time and combining the results of the remaining studies. The trends of associations remained consistent in sensitivity analyses, which indicated that the combined results were statistically stable.

3.4. Publication biases {#clc23282-sec-0015}
-----------------------

Funnels plots were employed to estimate whether our combined results may be influenced by publication biases. Funnel plots of every comparison were symmetrical, which indicated that the combined results were unlikely to be seriously impacted by overt publication biases (see Figure [S1](#clc23282-supitem-0001){ref-type="supplementary-material"}).

4. DISCUSSION {#clc23282-sec-0016}
=============

The A/G variant of rs1799889 polymorphism is associated with a guanosine insertion at the −675 site of the PAI.[15](#clc23282-bib-0015){ref-type="ref"} Past pre‐clinical studies also demonstrated that the transcriptional activity of A allele was significantly higher than that of the G allele.[16](#clc23282-bib-0016){ref-type="ref"}, [17](#clc23282-bib-0017){ref-type="ref"} So theoretically, it is possible that carriers of the A allele were more prone to thrombotic disorders compared to carriers of the G allele. Recently, many genetic association studies assessed association between *PAI‐1* rs1799889 A/G polymorphism and VTE, yet the findings were somehow conflicting. Thus, this meta‐analysis was performed by us to more comprehensively analyze relationship between rs1799889 polymorphism and VTE. The combined results demonstrated that *PAI‐1* rs1799889 A/G polymorphism was significantly associated with VTE in both Caucasians and East Asians. Further analyses obtained similar positive findings in these with DVT and these with Factor V Leiden mutation. The trends of associations remained consistent in sensitivity analyses, which indicated that the combined results were stable.

To better understand the combined results of this meta‐analysis, some points should be considered. Firstly, the etiology of VTE is complex, so we recommend future studies to conduct haplotype analyses and investigate gene‐gene interactions to more precisely analyze the effects of genetics on disease susceptibility.[18](#clc23282-bib-0018){ref-type="ref"} Secondly, environmental factors may also affect relationship between *PAI‐1* rs1799889 A/G polymorphism and PAI. Unfortunately, the majority of eligible publications only focused on genetic associations, so we could not estimate genetic‐environmental interactions in this meta‐analysis.[19](#clc23282-bib-0019){ref-type="ref"} Thirdly, this meta‐analysis was designed to assess associations between all *PAI‐1* polymorphisms and VTE. Nevertheless, only rs1799889 polymorphism was analyzed by us because no any other *PAI‐1* polymorphisms were studied by at least two different studies. Fourthly, it should be noted that in 2014, Wang et al also performed a meta‐analysis to investigate association between rs1799889 polymorphism and VTE.[20](#clc23282-bib-0020){ref-type="ref"} Since many related articles were published after this meta‐analysis, an updated study like ours is warranted. The sample size of the current meta‐analysis was around 50% larger than that of the previous meta‐analysis (14 806 subjects vs 9254 subjects), so our work should be considered as a valuable supplement to pre‐existing literatures. Consistent with findings of the previous meta‐analysis, we also confirmed that rs1799889 polymorphism was associated with an elevated susceptibility to VTE in both Caucasians and East Asians. The results of these two meta‐analyses indicated that *PAI‐1* rs1799889 polymorphism might serve as one of the predisposing factors of VTE. Subgroup analyses by established risk factors of VTE were also further performed by us. Nevertheless, since these analyses were only based on limited number of participants, the findings of these analyses should be considered as only exploratory, and further experimental studies should try to confirm these results. Besides, more stratified analyses should also be conducted by future meta‐analyses if there are sufficient data to support additional analyses for other established risk factors of VTE. Fifthly, although we also conducted subgroup analyses by type of disease in this meta‐analysis, it is noteworthy that studies only focused on PE were scare, so the results of subgroup analyses by type of disease should also be taken as exploratory. Future studies are still needed to confirm these findings.

Some limitations of this meta‐analysis should also be mentioned. Firstly, the results regarding associations between polymorphisms in *PAI‐1* rs1799889 polymorphism and VTE were based on combining unadjusted findings of eligible publications due to lack of raw data.[21](#clc23282-bib-0021){ref-type="ref"} Secondly, gray literatures were not searched. So although funnel plots of every comparison were symmetrical, it is still possible that the combined results may be affected by publication biases.[22](#clc23282-bib-0022){ref-type="ref"}, [23](#clc23282-bib-0023){ref-type="ref"}

5. CONCLUSIONS {#clc23282-sec-0017}
==============

In summary, the combined results of this meta‐analysis proved that *PAI‐1* rs1799889 A/G polymorphism may serve as one of the predisposing factors of VTE in both Caucasians and East Asians, especially in these with DVT and these with Factor V Leiden mutation. Further studies with larger sample sizes still need to verify our findings. Besides, given that the pathogenesis of VTE is complex, despite our comprehensive analyses, we still recommend further studies to explore gene‐gene interactions and gene‐environmental interactions in the development of VTE.
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